Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Cardinal Health, Inc. reported strong financial and operational results for the first quarter of fiscal year 2025, primarily driven by its Pharmaceutical and Specialty Solutions segment.</li><li>CEO Jason Hollar highlighted the company's effective management amidst a customer transition in its largest business segment, which still achieved a 16% growth in segment profit.</li><li>The demand across various pharmaceutical categories, notably specialty and consumer health, played a significant role in this growth.</li></ul>

Cardinal Health, Inc. reported strong financial and operational results for the first quarter of fiscal year 2025, primarily driven by its Pharmaceutical and Specialty Solutions segment.CEO Jason Hollar highlighted the company's effective management amidst a customer transition in its largest business segment, which still achieved a 16% growth in segment profit.The demand across various pharmaceutical categories, notably specialty and consumer health, played a significant role in this growth.

Cardinal Health: Can Its Strategic Acquisitions & Improving Market Position Be A Sustainable Growth Accelerator?  - Major Drivers

<ul><li>Cardinal Health Incorporated has shown a remarkable year with strong operational performance, achieving a considerable improvement in key financial metrics as highlighted in their Fourth Quarter FY 2024 Earnings.</li><li>During the fiscal year 2024, Cardinal Health reported striking growth in earnings per share (EPS), marking a 29% increase in both the fourth quarter and for the entire year.</li><li>The substantial growth in EPS throughout FY 2024 to $7.53 indicates a positive trajectory exceeding the company’s initial guidance significantly.</li></ul>

Cardinal Health Incorporated has shown a remarkable year with strong operational performance, achieving a considerable improvement in key financial metrics as highlighted in their Fourth Quarter FY 2024 Earnings.During the fiscal year 2024, Cardinal Health reported striking growth in earnings per share (EPS), marking a 29% increase in both the fourth quarter and for the entire year.The substantial growth in EPS throughout FY 2024 to $7.53 indicates a positive trajectory exceeding the company’s initial guidance significantly.

Cardinal Health Inc.: How Are They Achieving Specialty Business Growth Despite Nonrenewal Challenges! - Major Drivers

<ul><li>Cardinal Health, Inc., a provider of healthcare products and services, reported its Q3 FY2024 financial performance.</li><li>The quarter displayed broad-based growth as the company worked on its four strategic priorities, eventually leading to growth and raised outlook for the fiscal year '24.</li><li>The pharmaceutical and specialty solutions business showed strong growth, riding on ongoing stability in pharmaceutical demand.</li></ul>

Cardinal Health, Inc., a provider of healthcare products and services, reported its Q3 FY2024 financial performance.The quarter displayed broad-based growth as the company worked on its four strategic priorities, eventually leading to growth and raised outlook for the fiscal year '24.The pharmaceutical and specialty solutions business showed strong growth, riding on ongoing stability in pharmaceutical demand.

Cardinal Health: Deep-Rooted Market Relationships & Competitive Edge! - Major Drivers

<ul><li>Cardinal Health has recently announced its financial results for the second quarter of fiscal year 2024.</li><li>CEO Jason Hollar and CFO Aaron Alt expressed satisfaction with the progress the company has made, demonstrating strong profit growth in both segments and expected growth for 7% to 9% in segment profit for fiscal 2024.</li><li>Cardinal Health's acquisition of Specialty Networks is seen as a key step in enhancing the company's specialty growth strategy.</li></ul>

Cardinal Health has recently announced its financial results for the second quarter of fiscal year 2024.CEO Jason Hollar and CFO Aaron Alt expressed satisfaction with the progress the company has made, demonstrating strong profit growth in both segments and expected growth for 7% to 9% in segment profit for fiscal 2024.Cardinal Health's acquisition of Specialty Networks is seen as a key step in enhancing the company's specialty growth strategy.

Cardinal Health: Expanding Acquisitions Portfolio With Specialty Networks & Other Major Drivers

<ul><li>Cardinal Health delivered a solid result and managed an all-around beat in the last quarter, exceeding expectations and achieving significant milestones.</li><li>Consolidated enterprise results showcased a 10% increase in total revenue to $54.8 billion, primarily fueled by the Pharma segment.</li><li>Despite flat revenue of $3.8 billion in the Medical segment, the company exceeded expectations in Q1.</li></ul>

Cardinal Health delivered a solid result and managed an all-around beat in the last quarter, exceeding expectations and achieving significant milestones.Consolidated enterprise results showcased a 10% increase in total revenue to $54.8 billion, primarily fueled by the Pharma segment.Despite flat revenue of $3.8 billion in the Medical segment, the company exceeded expectations in Q1.

Cardinal Health: The Powerhouse Behind Today’s Medical and Pharmaceutical Breakthroughs! - Major Drivers

United States

Cardinal Health, Inc. provides complementary products and services to healthcare providers and manufacturers.  The Company's services include pharmaceutical distribution, health-care product manufacturing, distribution and consulting services, drug delivery systems development, pharmaceutical packaging, automated dispensing systems manufacturing, and retail pharmacy franchising.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cardinal Health (CAH US)

Cardinal Health: Can Its Strategic Acquisitions & Improving Market Position Be A Sustainable Growth Accelerator? - Major Drivers

Cardinal Health, Inc. reported strong financial and operational results for the first quarter of fiscal year 2025, primarily driven by its...

Baptista Research

Cardinal Health Inc.: How Are They Achieving Specialty Business Growth Despite Nonrenewal Challenges! - Major Drivers

Cardinal Health Incorporated has shown a remarkable year with strong operational performance, achieving a considerable improvement in key...

Baptista Research

Cardinal Health: Deep-Rooted Market Relationships & Competitive Edge! - Major Drivers

Cardinal Health, Inc., a provider of healthcare products and services, reported its Q3 FY2024 financial performance. The quarter displayed...

Baptista Research

Cardinal Health: Expanding Acquisitions Portfolio With Specialty Networks & Other Major Drivers

Cardinal Health has recently announced its financial results for the second quarter of fiscal year 2024. CEO Jason Hollar and CFO Aaron Alt...

Baptista Research

Cardinal Health: The Powerhouse Behind Today’s Medical and Pharmaceutical Breakthroughs! - Major Drivers

Cardinal Health delivered a solid result and managed an all-around beat in the last quarter, exceeding expectations and achieving significant...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)